Research Analysts Set Expectations for CRDL Q3 Earnings

Key Points

• Brookline Capital Markets cut estimates: the firm lowered Q3 2026 EPS to ($0.08) from ($0.07) and trimmed Q4 and FY2026 forecasts to ($0.09) and ($0.31), introducing near‑term downside pressure on CRDL.
• Mixed analyst sentiment: HC Wainwright and Canaccord maintain "Buy" ratings with $9 and $8 targets, but the MarketBeat consensus remains a "Hold" with an $8.50 price target.
• Valuation gap with recent beat: CRDL trades around $1.39 (market cap ≈ $155M) despite reporting ($0.05) EPS that beat estimates, highlighting a large gap between current share price and analyst price targets.

Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Equities researchers at Brookline Capital Markets reduced their Q3 2026 EPS estimates for shares of Cardiol Therapeutics in a research report issued on Wednesday, April 1st. Brookline Capital Markets analyst F. Ahmed now anticipates that the company will post earnings per share of ($0.08) for the quarter, down from their prior forecast of ($0.07). The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.33) per share. Brookline Capital Markets also issued estimates for Cardiol Therapeutics' Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.31) EPS.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) last announced its earnings results on Monday, March 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.04.

CRDL has been the topic of several other research reports. HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of Cardiol Therapeutics in a research report on Tuesday, February 10th. Canaccord Genuity Group reiterated a "buy" rating and set a $8.00 price objective on shares of Cardiol Therapeutics in a research report on Monday. upgraded shares of Cardiol Therapeutics to a "strong-buy" rating in a report on Tuesday, February 3rd. Finally, Wall Street Zen raised shares of Cardiol Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $8.50.

Cardiol Therapeutics Trading Down 0.4%

NASDAQ CRDL traded down $0.01 during trading hours on Tuesday, hitting $1.39. 529,314 shares of the company were exchanged, compared to its average volume of 545,432. Cardiol Therapeutics has a 52 week low of $0.80 and a 52 week high of $1.59. The company has a quick ratio of 3.89, a current ratio of 3.89 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average price of $1.06 and a 200 day moving average price of $1.05. The stock has a market cap of $154.87 million, a PE ratio of -4.95 and a beta of 0.82.

Institutional Investors Weigh In On Cardiol Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE grew its holdings in Cardiol Therapeutics by 136.2% during the 2nd quarter. Bank of America Corp DE now owns 26,455 shares of the company's stock worth $36,000 after acquiring an additional 15,255 shares in the last quarter. Simplex Trading LLC lifted its holdings in Cardiol Therapeutics by 96.9% during the fourth quarter. Simplex Trading LLC now owns 32,197 shares of the company's stock worth $31,000 after buying an additional 15,842 shares during the period. Security National Bank of Sioux City Iowa IA bought a new stake in Cardiol Therapeutics during the fourth quarter valued at about $31,000. Boyer Financial Services Inc. bought a new stake in Cardiol Therapeutics during the fourth quarter valued at about $33,000. Finally, AdvisorShares Investments LLC grew its stake in Cardiol Therapeutics by 7.3% in the fourth quarter. AdvisorShares Investments LLC now owns 597,977 shares of the company's stock valued at $570,000 after purchasing an additional 40,589 shares during the last quarter. 12.49% of the stock is owned by institutional investors.

Key Headlines Impacting Cardiol Therapeutics

Here are the key news stories impacting Cardiol Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a "Buy" rating and a $9.00 price target, and materially tightened/raised its EPS outlook — forecasting quarter-by-quarter EPS of ($0.06) and raising FY2026 to ($0.27) (from $0.41) and FY2027 to ($0.34) (from $0.51). Those upward revisions and the high price target are constructive for sentiment. MarketBeat: HC Wainwright Estimates
• Positive Sentiment: Canaccord Genuity reaffirmed its "Buy" rating and set an $8.00 target, reiterating bullish analyst support and providing an additional near-term catalyst for buyers. Benzinga: Canaccord Reaffirmation
• Neutral Sentiment: Consensus full‑year EPS expectations remain negative (around ($0.33) per share), so despite analyst activity the company is still expected to report losses — this limits how strongly upgrades will translate to valuation changes. MarketBeat: Consensus Estimates
• Negative Sentiment: Brookline Capital Markets trimmed near-term and full‑year EPS forecasts (Q3 to ($0.08) from ($0.07), Q4 to ($0.09), and FY2026 to ($0.31) from ($0.29)), a downgrade that introduces downward pressure and highlights execution/forecast risk. MarketBeat: Brookline Estimate Cuts

About Cardiol Therapeutics

Cardiol Therapeutics Inc NASDAQ: CRDL is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company's lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.